On 15 October 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended authorising Foundayo, an oral treatment containing orforglipron, for weight management and type 2 diabetes. It is a significant development for a drug class best known for injectable products.
But a CHMP recommendation does not mean that the pill has already been authorised in the European Union or is available in Romanian pharmacies. On 19 October, the EMA page for Foundayo indicated that a European Commission decision was still pending. Even if European authorisation is granted, further questions remain: when the product will be launched locally, what it will cost and whether it will be included in a reimbursement scheme.
For further context, see WHO recommends a new approach to obesity in children and adolescents, which examines an issue directly related to this topic.
In brief: the CHMP’s positive scientific opinion is confirmed. It has not yet been confirmed that Foundayo can be prescribed, purchased or reimbursed in Romania.
What the CHMP actually decided on the GLP-1 pill
The CHMP is the EMA’s scientific committee, which assesses the quality, safety and efficacy of medicines. Its positive opinion recommends granting a marketing authorisation through the EU’s centralised procedure. The final legal decision, however, rests with the European Commission.
These are three distinct stages, with different implications for patients:
- A positive CHMP opinion means that the scientific assessment has reached a favourable conclusion.
- A European Commission decision is the authorisation valid in EU member states for centrally approved medicines.
- Access in Romania still depends on the company’s decision to launch the product, its price, distribution, prescribing rules and, separately, any reimbursement decisions.
The European Commission publishes central authorisations in the Union Register of medicinal products. The EMA says detailed product documents, including final information for healthcare professionals and patients, will be published after authorisation is granted.
What orforglipron is and why it can be taken orally
Foundayo contains orforglipron, a GLP-1 receptor agonist. Medicines in this class can affect blood-glucose control and appetite, which is why, depending on the product and indication, they are used in type 2 diabetes and in medical weight management.
Orforglipron’s distinguishing feature is that the EMA describes it as a small, non-peptide molecule, available as a film-coated tablet taken once a day. According to the EMA announcement on the CHMP opinion, the product could be taken with or without food, on prescription.
This formulation may matter to people who prefer to avoid injections. It does not, in itself, show that the treatment will be more effective, safer or easier to follow than all injectable alternatives. A tablet also involves a daily routine, while treatment response, tolerability and the choice of therapy remain individual matters.
Who the treatment may be intended for
In the positive opinion, the proposed indication for weight management concerns adults with a body mass index (BMI) of at least 30 kg/m², or those with a BMI from 27 to under 30 kg/m² who have at least one weight-related condition. The treatment is intended as an adjunct to a healthy diet and physical activity, not a replacement for them.
For type 2 diabetes, the EMA describes its use in adults whose condition is insufficiently controlled, either on its own when metformin is considered unsuitable or in combination with other diabetes medicines.
These proposed criteria do not support the use of a “weight-loss pill” for cosmetic weight loss or self-medication. The choice of a GLP-1 receptor agonist should take account of diagnoses, other treatments, medical history and the monitoring required. People already being treated for diabetes or obesity should not stop or alter their regimen without consulting a doctor.
What the studies show — and the limits of comparisons
For weight management, the phase 3 ATTAIN-1 study, published in the New England Journal of Medicine, followed adults with obesity for 72 weeks. Orforglipron produced greater weight reductions than placebo. In the group receiving 36 mg under the study protocol, 54.6% of participants achieved a reduction of at least 10% of their initial body weight, compared with 12.9% in the placebo group.
In early treatment of type 2 diabetes, the ACHIEVE-1 study reported reductions in HbA1c and body weight compared with placebo after 40 weeks. In both programmes, commonly reported adverse reactions were gastrointestinal, including nausea, vomiting and diarrhoea.
The findings are relevant, but they do not support a claim that orforglipron is “better” than semaglutide, tirzepatide or any other injectable treatment. The studies cited are not a single, direct and comprehensive comparison with all of those alternatives. Nor do averages achieved in a study amount to a promise for every patient.
One useful clarification: the strengths listed by the EMA for Foundayo should not be compared milligram for milligram with doses of other GLP-1 medicines. The substances differ, and the number of milligrams is not a direct measure of clinical effect.
What is known in Romania — and what is not yet known
On 19 October 2026, Romania’s National Agency for Medicines and Medical Devices (ANMDMR) published a statement on the new orally administered GLP-1 medicine referring readers to EMA information. However, the statement does not announce that the product is already being marketed in Romania, and gives no price, launch date, stock or reimbursement information.
In a setting where incretin-mimetic treatments are already used in Romania, the difference between European authorisation and actual access is worth following closely. EU authorisation would allow the product to be marketed, but would not automatically require the company to launch it simultaneously in every member state, nor would it by itself set a country’s reimbursement level.
Until final documents and specific national information are published, the most cautious conclusion is straightforward: Foundayo is a potential new oral option at an advanced regulatory stage, not a medicine confirmed as available in Romania. Avoid products sold online as “orforglipron” from unauthorised sources; their authenticity, dosage and safety cannot be guaranteed.
Frequently asked questions
Has the EMA approved Foundayo for Romania?
The CHMP, the EMA’s scientific committee, issued a positive opinion on 15 October 2026. As of 19 October 2026, the European Commission’s final decision was still pending. A CHMP opinion is not the same as final authorisation, nor does it mean the medicine is available in Romania.
Is Foundayo already available in Romanian pharmacies?
As of the date checked in the sources consulted, there was no official announcement on Foundayo’s commercial launch, price, stock or reimbursement in Romania.
Does the oral form mean Foundayo is better than GLP-1 injections?
No. Some patients may prefer an oral formulation, but it does not automatically demonstrate greater efficacy, safety or adherence than injectable treatments. Direct clinical comparisons would be needed to draw such conclusions.
Sources consulted
- Foundayo — European Medicines Agency
- New oral GLP-1 medicine for weight management and type 2 diabetes — European Medicines Agency
- Union Register of medicinal products — European Commission
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — New England Journal of Medicine
- Press statement of 19 October 2026 — ANMDMR










Discuția cititorilor
Ai o opinie sau o întrebare despre acest articol? Spune-ne ce crezi.
Fii primul care deschide discuția.
Te rugăm să păstrezi un limbaj civilizat și să discuți la subiect. Comentariile spam sunt filtrate automat.